STOCK TITAN

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) announced that CEO Neil Warma will present at the 2024 BIO CEO & Investor Conference in New York. The company will also conduct one-on-one meetings during the event.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.

Presentation Details:
Presenter: Neil Warma, Chief Executive Officer
Date: Tuesday, February 27, 2024
Time: 11:00 am ET
Location: Plymouth Room, New York Marriott Marquis

ProMIS Neurosciences senior management will also conduct one-on-one meetings during the conference. For more information or to schedule a meeting, please visit the conference page here or contact ProMIS Neurosciences Investor Relations.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.

For further information:

Visit us at www.promisneurosciences.com

Please submit media inquiries to info@promisneurosciences.com.

For Investor Relations:

Stern Investor Relations
Anne Marie Fields, Managing Director
annemarie.fields@sternir.com
Tel. 212-362-1200


FAQ

When is Neil Warma scheduled to present at the 2024 BIO CEO & Investor Conference?

Neil Warma is scheduled to present on Tuesday, February 27, 2024, at 11:00 am ET.

Where will the presentation take place?

The presentation will take place in the Plymouth Room at the New York Marriott Marquis.

What is the focus of ProMIS Neurosciences Inc. at the conference?

ProMIS Neurosciences will focus on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases.

How can one schedule a meeting with ProMIS Neurosciences during the conference?

To schedule a meeting, one can visit the conference page or contact ProMIS Neurosciences Investor Relations.

ProMIS Neurosciences Inc. Common Shares (ON)

NASDAQ:PMN

PMN Rankings

PMN Latest News

PMN Stock Data

37.16M
10.81M
24.35%
17.71%
0.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
TORONTO

About PMN

promis™ neurosciences, inc. (tse: pmn, https://ca.finance.yahoo.com/q/bc?s=pmn.to), is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular alzheimer’s disease (ad) and amyotrophic lateral sclerosis (als). the company’s scientific foundation centers on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. several neurodegenerative diseases exhibit protein misfolding, such as ad, als, and parkinson’s disease (pd). recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. the company is focused on the discovery and development of precision therapeutics and companion diagnostics to combat the several strains of beta-amyloid (aβ) and tau i